SOURCE: IBC Life Sciences

September 18, 2006 13:33 ET

IBC'S Newly Expanded Event, Discovery-2-Diagnostics, to Take Place in Boston Next Week

WESTBOROUGH, MA -- (MARKET WIRE) -- September 18, 2006 -- IBC's newly expanded event, Discovery-2-Diagnostics, focusing on maximizing microarrays, biomarkers and molecular diagnostics to scientifically advance new discoveries and novel technologies, will be taking place September 25-27 at the Hynes Convention Center in Boston. It features three of IBC's highly regarded conferences: 13th Annual Chips to Hits®, 5th Annual Biomarkers, and 5th Annual Molecular Diagnostics. Download Brochure!

This is the largest and most unique event that focuses on the strategies, tool sets, and alternative uses of technologies and standards that will solve your challenges with the use of biomarkers through discovery to the clinic, proactive approaches to diagnostic commercialization and emerging applications and scientific advances for microarrays. During the three day event, the most prominent executives, scientists and developers within pharma, biotech, academia, and government will gather to attend interactive sessions, debates and panel discussions on the emerging challenges and opportunities within the market. The D2D Exhibition offers 100+ exhibiting companies providing a diverse set of products and solutions that will allow your company to facilitate the processes needed to move down the pipeline from discovery to diagnostics.

Keynote Presentations:

Hear the Results from the FDA-Sponsored Microarray Quality Control Study
Facilitated by Leming Shi, Ph.D., NCTR/FDA

Technologies and the Impact of Personal Genomics
George M. Church, Ph.D., Harvard Medical School

Functional Proteomics for Biomarker and Target Identification
Joshua LaBaer, Ph.D., Harvard Medical School Institute of Proteomics

Moving Biomarkers into Diagnostics
Werner Kroll, Head of Biomarker Development, Novartis

Integrated Diagnostics for Breast Cancer: Yesterday, Today and Tomorrow
Jeffrey S. Ross, M.D., Cyrus Strong Merrill Professor and Chair Department
of Pathology and Laboratory Medicine, Albany Medical College

Clinical Grade Quality Control for Multiplex Assays: Can we Do It?
Stephen R. Master, M.D., Ph.D., FCAP, University of Pennsylvania School of
Medicine: and Hospital of the University of Pennsylvania

Co-Development of Drugs and Diagnostic Devices -- Don't Forget the
Steven Gutman, M.D., FDA

Download Brochure!

ATTENTION CALENDAR EDITORS! For more information on attending Discovery-2-Diagnostics in Boston, Massachusetts visit

Contact Information

  • From: IBC Life Sciences
    Contact: Kerry Patterson
    Email: Email Contact